Female Urethral Stricture
Female urethral stricture (FUS) is a pathological narrowing of the female urethra resulting from scar tissue formation — a condition that is far less common than its male counterpart, significantly underdiagnosed, and frequently mismanaged with repeated dilations before definitive reconstruction is considered. Bladder outlet obstruction (BOO) accounts for only 2.7–8% of women referred for voiding dysfunction, and true anatomical urethral stricture represents 4–20% of those cases — yet among women with refractory lower urinary tract symptoms, FUS is a frequently overlooked diagnosis.[1][2]
Epidemiology
FUS is considered rare but is substantially underdiagnosed due to non-specific presentation, lack of a standardized diagnostic definition, and historical tendency to attribute obstructive voiding symptoms in women to functional rather than anatomical causes.[3] There is no high-quality population prevalence data. An estimated 10% of women presenting with obstructive voiding symptoms will have a true anatomical urethral stricture on objective evaluation.[4]
Publications on female urethroplasty have increased substantially since 2021, reflecting growing recognition and referral to specialized centers.[3]
Etiology
| Category | Key Causes |
|---|---|
| Iatrogenic | Traumatic or repeated urethral catheterization (most common); urethral dilation itself causing fibrosis; pelvic surgery; radiation therapy; prior anti-incontinence procedures |
| Lichen sclerosus (LS) | Progressive inflammatory fibrosis; typically distal/meatal; recurs in genital tissue; requires oral mucosa for repair |
| Inflammatory | Recurrent UTIs; urethritis; sexually transmitted infections |
| Traumatic | Blunt pelvic trauma; obstetric injury (cephalopelvic disproportion, instrumented delivery) |
| Idiopathic | No identifiable cause; diagnosis of exclusion |
| Other | Malignancy; radiation; urethral or vaginal atrophy; lichen planus |
:::warning Catheterization as a Cause Iatrogenic injury from urethral catheterization is the single most common identifiable etiology. This includes both single traumatic catheterizations and — critically — repeated urethral dilations performed to treat stricture, which themselves cause progressive spongiofibrotic injury and worsen the underlying disease. Urethral dilation has been described as "often overused and unnecessary, leading to significant healthcare costs" in the management of FUS.[2] :::
Diagnostic Criteria and Workup
Diagnosis is challenging due to non-specific symptoms and the absence of a universally accepted diagnostic definition. A structured workup is essential.
Clinical Presentation
Women with FUS most commonly present with obstructive voiding symptoms:[4][3]
- Weak or reduced urinary stream
- Urinary hesitancy and straining to void
- Incomplete bladder emptying
- Post-void dribbling
- Urinary frequency, urgency, nocturia (secondary to elevated post-void residual)
- Recurrent urinary tract infections
- Urinary retention (acute or chronic)
- Dysuria, urethral pain
:::note Diagnostic Challenge In contrast to men, obstructive voiding symptoms in women are frequently attributed to overactive bladder or functional voiding dysfunction. FUS should be considered in any woman with persistent obstructive voiding symptoms refractory to behavioral and pharmacological management, prior to labeling the condition as idiopathic or functional. :::
Diagnostic Modalities
| Test | Findings in FUS | Notes |
|---|---|---|
| Uroflowmetry | Plateau-shaped (flat-top) curve; reduced Qmax | Same pattern as in men; highly suggestive when combined with symptoms |
| Post-void residual (PVR) | Elevated | Confirms incomplete emptying |
| Urethral calibration | Inability to pass 14 Fr catheter is almost pathognomonic | Quick, office-based; inability to catheterize with small bore catheter = strong presumptive diagnosis |
| Cystourethroscopy | Direct visualization of narrowing, epithelial pallor, scarring | Gold standard for visualization; does not reliably assess stricture length |
| Voiding Cystourethrography (VCUG) | Classic "wine glass" appearance — prestenotic urethral dilation tapering to narrowing | Defines location and length; essential for surgical planning |
| Video-urodynamics | Combines pressure-flow study with real-time fluoroscopy | Best for complex cases, especially when neurogenic or functional component suspected |
| Pelvic MRI | Evaluates periurethral fibrosis, urethral diverticulum, pelvic anatomy | Indicated for complex anatomy, recurrent strictures, suspected diverticulum |
| Urodynamics | Rules out detrusor underactivity, neurogenic bladder | Indicated when symptoms exceed anatomical findings or treatment response is unexpected |
:::tip The Wine Glass Sign On VCUG, the female urethra with stricture demonstrates a pathognomonic "wine glass" or "spinning top" deformity — the bladder neck and proximal urethra dilate proximally to the obstruction, tapering sharply at the stricture site. This fluoroscopic appearance, combined with clinical symptoms, is sufficient to establish the diagnosis and plan surgical treatment. :::
Classification
FUS is classified by anatomical location and stricture length:
By Location
| Location | Characteristics |
|---|---|
| Distal / Meatal | Visible at introitus; most commonly LS-related; amenable to meatoplasty or short flap procedures |
| Mid-urethral | Most common location; typically iatrogenic or idiopathic |
| Proximal (near bladder neck) | Least common; most complex; associated with pelvic surgery or radiation |
| Multifocal / Panurethral | Multiple levels; typically LS-related or after radiation |
By Length
- Very short (<0.5 cm): Meatoplasty may suffice
- Short (<2 cm): Flap procedures appropriate
- Long (≥2 cm): Graft urethroplasty required; complex cases may need staged repair
Treatment
Treatment Ladder
Observation (asymptomatic)
↓
Urethral Dilation or DVIU (first episode; short, non-LS strictures)
↓
Drug-Coated Balloon Dilation (recurrent bulbar-equivalent strictures)
↓
Urethroplasty (definitive; indicated for LS, recurrence, long strictures)
Observation
Asymptomatic, incidentally discovered urethral narrowing without obstructive symptoms or elevated PVR may be observed. Active surveillance with uroflowmetry and PVR is appropriate.
Urethral Dilation and DVIU
Urethral dilation remains the most commonly performed first-line treatment despite limited long-term efficacy.[4]
- Composite success rate: ~47%
- Without prior dilations: 58%
- After prior dilations: 27%
- Success decreases substantially with each subsequent dilation
- Repeat dilation risks progressive urethral fibrosis and worsening stricture
:::danger Repeated Dilation Repeated urethral dilation should not be offered for recurrent stricture — each dilation increases spongiofibrosis and makes subsequent reconstruction more complex. After one failed dilation, definitive urethroplasty should be offered. After dilation, urethroplasty should be delayed at least 3 months to allow stricture maturation.[4] :::
Drug-Coated Balloon (Optilume DCB)
Optilume drug-coated balloon dilation delivers paclitaxel to the urethral mucosa to inhibit scar recurrence. A 2025 prospective study enrolled 14 women with recurrent FUS (mean 4.3 prior interventions, range 0–40):[5]
- Dilation performed at 30 Fr pressure for 10 minutes
- Mean age: 52.3 years; mean follow-up: 12 months
- 91.7% (11/12) free from recurrence at follow-up
- Sphincter function fully preserved in all patients
- 2 patients had resolution of pre-existing incontinence after stricture treatment
- Well tolerated; no major complications
The AUA (2023 amendment) restricts DCB use to recurrent bulbar strictures in men and notes insufficient data for penile strictures. In women, data are emerging but limited to small series — Optilume represents a promising bridge between failed dilation and urethroplasty in selected patients.
Urethroplasty
Urethroplasty is the definitive treatment for FUS. Success rates are superior to all endoscopic approaches and should be offered after the first failed dilation, for any LS-related stricture, for long strictures, and for patient preference for definitive repair.[1][2]
Technique Selection by Stricture Characteristics
| Procedure | Indication | Success Rate | Key Consideration |
|---|---|---|---|
| Heineke-Mikulicz meatoplasty | Meatal stricture only (<0.5 cm) | ~96% | Contraindicated in LS — will recur; not for strictures >0.5 cm |
| Anterior vaginal wall flap (Blandy) | Short strictures (<2 cm) | ~91% | Risk of inward/vaginal voiding stream; requires good vaginal tissue quality |
| Vestibular flap (Montorsi) | Short distal strictures (<2 cm) | ~91% | Inverted-Y incision; catheter 1 day only; risk of anterior deflection of stream |
| Lateral vaginal wall flap (Orandi) | Longer strictures (>2 cm) | Not reported separately | Island flap on lateral pedicle; 3-week catheter |
| Dorsal onlay graft (oral mucosa) | Mid/long; LS; recurrent; if future sling anticipated | ~94% | Graft quilted to clitoral bodies; lower fistula risk; technically demanding |
| Ventral onlay graft (oral mucosa) | Mid/long; well-vascularized vaginal bed available | ~94% | Higher fistula risk; Martius flap reduces this |
| Vaginal/labial graft (ventral onlay) | Non-LS cases with good local tissue | ~80% | Not appropriate in LS or vaginal atrophy |
Graft Material Selection
Oral mucosa (buccal or lingual) is the graft of choice for female urethroplasty when free graft reconstruction is required:[4][3]
- Success rate: ~94% (vs. 80% for vaginal/labial grafts)
- Mandatory in lichen sclerosus — genital tissue will recur with LS involvement
- Should replace vaginal grafts when vaginal atrophy is present
- Buccal and lingual grafts are equivalent
Contraindications to genital tissue use:
- Active or suspected lichen sclerosus (any stage)
- Vaginal atrophy
- Prior pelvic radiation involving vaginal tissue
- Prior failed vaginal graft
Dorsal vs. Ventral Onlay
| Feature | Dorsal Onlay | Ventral Onlay |
|---|---|---|
| Graft bed | Clitoral bodies (highly vascularized) | Anterior vaginal wall |
| Fistula risk | Lower | Higher (mitigated by Martius flap) |
| Technical difficulty | Higher (dissection between clitoral bodies) | More familiar anatomically |
| Future SUI surgery | Preferred — preserves ventral tissue for sling | Compromises ventral tissue |
| Bleeding risk | Higher (clitoral blood supply) | Lower |
:::tip Choosing the Approach Select dorsal onlay when:
- Future suburethral sling insertion is anticipated (preserves ventral suburethral tissue)
- Ventral vaginal tissue is compromised (atrophy, prior radiation, fistula)
- Lichen sclerosus with distal extension
Select ventral onlay when:
- Good ventral tissue quality available
- Surgeon has greater familiarity with ventral approach
- Use Martius flap to reduce fistula risk in all ventral cases with any concern about tissue quality :::
Martius Flap
The Martius fibrofatty flap from the labium majus is a critical adjunct in female urethroplasty:[4]
- Harvest: Sagittal incision over labium majus; fibrofatty pad harvested
- Blood supply: Internal and external pudendal arteries (dual supply — robust)
- Transposition: Subcutaneous tunnel to interpose between urethra and vagina
- Indications: Any ventral urethroplasty with compromised tissue; recurrent stricture; prior fistula; radiation; poor tissue quality
- Benefits: Reduces urethrovaginal fistula risk; provides vascularized tissue bed for graft
- Enables: Subsequent suburethral sling insertion (the Martius flap acts as a vascularized layer protecting the urethra from sling erosion)
- Complications: Labial hematoma; minor cosmetic change; decreased labial sensitivity
Postoperative Care
| Parameter | Recommendation |
|---|---|
| Vaginal packing | 24 hours postoperatively (hemostasis) |
| Catheter duration — vestibular flap | 1 day |
| Catheter duration — vaginal flap | 7–10 days |
| Catheter duration — graft urethroplasty | 2–3 weeks |
| Catheter removal criterion | Negative retrograde/voiding urethrography confirming patent repair |
| Time to urethroplasty after dilation | Minimum 3 months (stricture maturation) |
| Follow-up | Uroflowmetry + PVR at 6 weeks, 3 months, 6 months, then annually |
Complications
| Complication | Notes |
|---|---|
| Urethrovaginal fistula | Ventral approach risk; mitigated by Martius flap |
| Stress urinary incontinence | Theoretical; not commonly observed clinically; dorsal approach preferred when at risk |
| Graft sacculation | Free graft complication; usually asymptomatic |
| Stream abnormality | Anterior deflection (vestibular flap); vaginal voiding (Blandy flap) |
| Recurrent meatal stenosis | Particularly with LS — requires lifelong surveillance |
| Clitoral injury | Dorsal approach; largely overstated with careful technique |
| Labial hematoma/seroma | Martius flap harvest site |
Outcomes Summary
| Treatment | Success Rate | Key Caveat |
|---|---|---|
| Urethral dilation (first episode) | 47–58% | Declines with each repeat |
| Urethral dilation (after prior dilations) | 27% | Should not be repeated |
| Meatoplasty | ~96% | Meatal only; CI in LS |
| Vaginal flap (Blandy/Montorsi) | ~91% | Short strictures; good tissue |
| Oral mucosa graft (dorsal or ventral onlay) | ~94% | Gold standard for graft urethroplasty |
| Vaginal/labial graft | ~80% | Avoid in LS and atrophy |
| Optilume DCB (2025 data) | 91.7% (n=12, 12 mo) | Preserves continence; recurrent cases |
:::note Standardization Gap A 2025 narrative review of 22 studies (2019–2024) found that while "success rates appear to fairly agree amongst authors," significant heterogeneity in outcome measures limits cross-study comparisons. The authors recommend standardized reporting protocols incorporating patient-reported outcomes (FSFI, symptom scores, QoL instruments) alongside anatomical success to enable meaningful evidence synthesis.[3] :::
References
1. Chakraborty JN, Enganti B, Nayak P. "Female Urethroplasty: A Critical Review of Indications, Techniques and Concerns." Int Urogynecol J. 2025. [PMID: 41204975]. doi:10.1007/s00192-025-06415-4
2. Turchi B, Lumen N, Verla W, Waterloos M. "Female urethral stricture disease: a narrative review on diagnosis, surgical techniques and outcomes." Int J Impot Res. 2025. [PMID: 40348941]. doi:10.1038/s41443-025-01079-6
3. West C, Lawrence A. "Female urethral stricture: review of current practice." World J Urol. 2019. [PMID: 30456711].
4. Waterloos M, Verla W. "Female Urethroplasty: A Practical Guide Emphasizing Diagnosis and Surgical Treatment of Female Urethral Stricture Disease." Biomed Res Int. 2019;2019:6715257. [PMID: 30906779]. doi:10.1155/2019/6715257
5. Jelisejevas LA, Tulchiner G, Kink P, Rehder P. "Does Optilume drug-coated balloon dilation compromise female sphincter function?" Int Urol Nephrol. 2025. [PMID: 40244519]. doi:10.1007/s11255-025-04513-2